Showing results (1-10 of 1,427,609) with videos related to
Sort By:
Pageof 142,761
Current Medical Research and Opinion|October 6, 2018
Examining quality of care for individuals treated for mental health using the HEDIS mental health quality measuresDaisy Ng-Mak, Krithika RajagopalanCurrent Medical Research and Opinion|April 8, 2018
Hospitalization risk in bipolar disorder patients treated with lurasidone versus other atypical antipsychoticsDaisy Ng-Mak, Rachel Halpern, Krithika Rajagopalan, et al.BMC Health Services Research|April 6, 2018
Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysisJohn W Newcomer, Daisy Ng-Mak, Krithika Rajagopalan, et al.Journal of Comparative Effectiveness Research|April 27, 2018
Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysisDaisy Ng-Mak, Vanita Tongbram, Kerigo Ndirangu, et al.Auris, Nasus, Larynx|January 18, 2011
Hearing loss after noise exposureRevadi Govindaraju, Rahmat Omar, Raman Rajagopalan, et al.Community Mental Health Journal|October 15, 2018
Implementation and Use of a Client-Facing Web-Based Shared Decision-Making System (MyCHOIS-CommonGround) in Two Specialty Mental Health ClinicsMolly Finnerty, Elizabeth Austin, Qingxian Chen, et al.Circulation Research|April 25, 2024
Understanding the Cardiovascular and Metabolic Health Effects of Air Pollution in the Context of Cumulative Exposomic ImpactsHaitham Khraishah, Zhuo Chen, Sanjay RajagopalanBioorganic & Medicinal Chemistry Letters|December 25, 2013
The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffoldsRaghavan Rajagopalan, Acintya Bandyopadhyaya, Desikan R Rajagopalan, et al.BMC Psychiatry|June 2, 2016
Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophreniaGeorge Awad, Daisy Ng-Mak, Krithika Rajagopalan, et al.Bioorganic & Medicinal Chemistry Letters|May 28, 2014
DDD-028: a potent potential non-opioid, non-cannabinoid analgesic for neuropathic and inflammatory painParthasarathi Rajagopalan, Heather Tracey, Zhoumou Chen, et al.Pageof 142,761